文献速递前列腺癌

恩杂鲁胺联合ADT在mHSPC不同亚组中的疗效:基于既往治疗、疾病体积和风险的分析

Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-08-21

ARCHES试验的事后分析评估恩杂鲁胺联合ADT在转移性激素敏感性前列腺癌(mHSPC)患者中的疗效,按既往局部/系统治疗、疾病体积和风险分组。结果显示恩杂鲁胺联合ADT显著改善影像学无进展生存期(rPFS)(HR 0.39;p<0.0001),且各亚组获益一致,多个次要终点也见获益。

要点

  • 恩杂鲁胺联合ADT显著改善mHSPC患者rPFS(HR 0.39;p<0.0001)。
  • 各亚组(既往局部/多西他赛治疗、疾病体积、风险)获益一致。
  • 多个次要临床终点在总体人群和所有亚组中均观察到获益。

核心结论

  • 恩杂鲁胺联合ADT在mHSPC患者中具有临床获益,不受既往局部和系统治疗、疾病体积和风险的影响。

研究设计与样本

  • ARCHES是一项全球、双盲、安慰剂对照的3期试验(NCT02677896),1150例mHSPC患者按1:1随机接受恩杂鲁胺(160 mg/天)联合ADT或安慰剂联合ADT,按既往多西他赛治疗和疾病体积分层。

主要发现

  • 恩杂鲁胺联合ADT显著改善rPFS(HR 0.39;p<0.0001)。
  • 基于既往局部治疗、多西他赛暴露、CHAARTED定义的疾病体积和LATITUDE定义的风险亚组中,rPFS改善相似。
  • 在总体人群和所有亚组中,多个次要临床终点均观察到恩杂鲁胺联合ADT的治疗获益。

关键数值与推荐

  • 恩杂鲁胺联合ADT组574例,安慰剂联合ADT组576例。
  • 主要终点为rPFS,次要终点包括至PSA进展时间、症状性骨骼事件、PSA和影像学缓解。
  • 亚组分析基于既往局部治疗、既往多西他赛暴露、CHAARTED疾病体积和LATITUDE风险组。

临床怎么用

  • 对于mHSPC患者,无论既往是否接受局部治疗或多西他赛、疾病体积和风险如何,均可考虑恩杂鲁胺联合ADT治疗。

局限性

  • 本文为事后分析,亚组结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While enzalutamide plus androgen deprivation therapy (ADT) significantly reduces the risk of radiographic progression-free survival (rPFS) and improves overall survival in metastatic hormone-sensitive prostate cancer (mHSPC), the efficacy in clinically relevant subgroups of patients based on prior local and systemic therapy, disease volume, and risk has not been analyzed to date. These post hoc analyses of the phase 3 ARCHES trial (NCT02677896) evaluated the efficacy of enzalutamide plus ADT according to prior local and systemic treatment, disease volume, and risk, assessed at trial baseline. METHODS: In ARCHES, a global, double-blind, placebo-controlled, phase 3 study, 1150 patients with mHSPC were randomized 1:1 to receive enzalutamide (160 mg/day) plus ADT or placebo plus ADT, stratified by prior docetaxel therapy and disease volume. Primary endpoint was rPFS. Secondary endpoints included time to prostate-specific antigen progression, symptomatic skeletal events, and prostate-specific antigen and radiographic responses. Analyses of clinical endpoints were completed by prior local therapy, prior docetaxel exposure, CHAARTED (NCT00309985)-defined disease volume, and LATITUDE (NCT01715285)-defined risk groups. RESULTS: Patients were randomized to enzalutamide plus ADT (n = 574) and placebo plus ADT (n = 576). Enzalutamide plus ADT significantly improved rPFS (hazard ratio: 0.39; p < 0.0001), with similar improvements reported in all subgroups based on prior local and docetaxel treatment, disease volume, and risk. Treatment benefits were observed with enzalutamide plus ADT in multiple secondary clinical endpoints in the overall population and all subgroups. CONCLUSIONS: Enzalutamide plus ADT demonstrated clinical benefit across all patients with mHSPC, irrespective of prior local and systemic treatment, disease volume, and risk.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Azad AA, Armstrong AJ, Alcaraz A, et al. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk. Prostate Cancer Prostatic Dis. 2021. PMID: 34420037. doi:10.1038/s41391-021-00436-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。